Pan-coronavirus fusion inhibitors as the hope for today and tomorrow.
10.1007/s13238-020-00806-7
- Author:
Xinling WANG
1
;
Shuai XIA
1
;
Yun ZHU
2
;
Lu LU
3
;
Shibo JIANG
4
Author Information
1. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
2. National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
3. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. lul@fudan.edu.cn.
4. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. shibojiang@fudan.edu.cn.
- Publication Type:Research Support, Non-U.S. Gov't
- MeSH:
Amino Acid Sequence;
Coronavirus/drug effects*;
Coronavirus Infections/drug therapy*;
Drug Design;
Humans;
Protein Structure, Secondary;
Spike Glycoprotein, Coronavirus/metabolism*;
Viral Fusion Protein Inhibitors/pharmacology*;
Viral Fusion Proteins/metabolism*
- From:
Protein & Cell
2021;12(2):84-88
- CountryChina
- Language:English
